Active specific immunotherapy (ASI). An immunological approach to ovarian cancer treatment

  • G. D. MacLean
  • B. M. Longenecker


The response rate of ovarian cancer to platinum based (cisplatin and carboplatin) chemotherapies has given cause for optimism in the management of metastatic ovarian cancer, but we are still faced with the challenge that more than 50% of these patients have died within five years of diagnosis and commencing chemotherapy. Alternative second line cytotoxic therapies have not significantly influenced the survival of women with residual or relapsing metastatic ovarian cancer. What can we offer the young woman who has been treated with cisplatin or carboplatin and who is at high risk of relapse because of bulky or high grade disease at presentation or because of a persisting elevated serum CA125 antigen level?


Ovarian Cancer Keyhole Limpet Hemocyanin Complement Dependent Cytotoxicity Active Specific Immunotherapy Metastatic Ovarian Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mitchell, M.S. (1992) Biomodulators in cancer treatment. J. Clin. Pharmacol, 32, 2–9.PubMedGoogle Scholar
  2. 2.
    Old, L.J. (1981) Cancer immunology: the search for specificity. G.H.A. Clowes Memorial Lecture. Cancer Res., 41, 361–75.PubMedGoogle Scholar
  3. 3.
    Hakomori, S. I. (1985) Aberrant glycosylation in cancer cell membranes as focused on glyco- lipids: overview and perspectives. Cancer Res., 45, 2405–14.PubMedGoogle Scholar
  4. 4.
    Hanisch, F.G., Uhlenbruek G., Egge, H. et al. (1989) A B72.3 second-generation monoclonal antibody (CC49) defines the mucin-carried carbohydrate epitope Galβ(l-3)[NeuAcα(2–6)]GalNAc. J. Biol. Chem., 370, 21–6.Google Scholar
  5. 5.
    Longenecker, B.M., Willans, D.J., MacLean, G.D. et al. (1987) Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers. J. Natl. Cancer Inst., 78,489–96.PubMedGoogle Scholar
  6. 6.
    MacLean, G.D., McEwan, A., Noujaim A.A. et al. (1991) Two novel monoclonal antibodies have potential for gynecologic cancer imaging. Antibody Immunocon. Radiopharm., 4, 297–308.Google Scholar
  7. 7.
    Fung, P.Y.S. and Longenecker, B.M. (1991) Specific immunosuppressive activity of epi- glycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3- HA). Cancer Res., 51,1170–6.PubMedGoogle Scholar
  8. 8.
    Fung, P.Y.S., Madej, M., Koganty, R. et al. (1990) Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res., 50, 4308–14.PubMedGoogle Scholar
  9. 9.
    MacLean, G.D. and Longenecker, B.M. (1991) Clinical significance of the Thomsen- Friedenreich antigen. Semin. Cancer Biol, 2,433–9.PubMedGoogle Scholar
  10. 10.
    Springer, G.F. (1984) T and Tn, General carcinoma autoantigens. Science, 244,1198–206.CrossRefGoogle Scholar
  11. 11.
    Itzkowitz, S.H., Bloom, E.J., Kokal, W.A. et al. (1990) Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer, 66, 1960–6.PubMedCrossRefGoogle Scholar
  12. 12.
    MacLean, G.D., Bowen-Yacyshyn, M.B., Samuel, J. et al. (1992) Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J. Immunother., 11,292–305.PubMedCrossRefGoogle Scholar
  13. 13.
    Crum, E. (1993) Effect of cisplatin upon expression of in vivo immune tumor resistance. Cancer Immunol Immunother., 36, 18–24.PubMedCrossRefGoogle Scholar
  14. 14.
    Nuti, M., Teramoto, Y.A., Mariani-Costantini, R. et al. (1982) A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int. J. Cancer, 29, 539–45.PubMedCrossRefGoogle Scholar
  15. 15.
    Kobayashi, H., Terao, T., Kawashima Y. et al. (1992) Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer, J. Clin. Oncol, 10, 95–101.Google Scholar
  16. 16.
    Longenecker, B.M., Reddish, M., Miles, D. et al. (1993) Synthetic tumor associated sialyl- Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res., in pressGoogle Scholar
  17. 17.
    MacLean, G.D., Reddish, M., Koganty, R.R. et al. (1993) Immunization of breast cancer patients using a synthetic sialyi-Tn glycocon jugate plus Detox adjuvant. Cancer Immunol Immunother 36, 215–22PubMedCrossRefGoogle Scholar
  18. 18.
    Ding. L. Lalani, E., Reddish, M. et al. (1992) Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUCl gene: effect of immunization of the growth of murine mammary adenocarcinoma cells transfected with the human MUCl gene.Cancer Immunol Immunother., 36, 9–17.CrossRefGoogle Scholar
  19. 19.
    De Bono, E. (1971) Practical Thinking, Penguin Book, Harmondsworth, Chapter 7.Google Scholar

Copyright information

© Chapman & Hall 1995

Authors and Affiliations

  • G. D. MacLean
  • B. M. Longenecker

There are no affiliations available

Personalised recommendations